COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Rush University Medical Center

S. Jain

VTE Prophylaxis After THA for Asian Population: Pharmacological Prop…

Arthroplasty Society in Asia

M. Mihara

VTE Prophylaxis After THA in the Asians: Messages from 2019 AP VTE C…

Arthroplasty Society in Asia

A. Tanavalee

VTE Prophylaxis After THA: Chinese Experience

Arthroplasty Society in Asia

H. Cai

New European Guidelines on Pulmonary Embolism: What Has Changed and …

PERT Consortium 2021

S. Konstantinides

Cancer-Associated Thrombosis: Defining, Risk Assessment, and Prognos…

BMFcases

T. Bat, M. Carrier

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Acute DVT: When to and When Not to Intervene?

Venous Edge

S. Elias, C. Pena, C. Huff, R. Winokur, K. BROWN

TCT 2022: Why Intervene on Submassive Pulmonary Embolism Patients?

TCT 2022 Conference Coverage

W. Jaber

Prevention and Treatment of Cancer-Associated Thrombosis: What Are t…

James Douketis

Catheter-Based Interventions for Acute Pulmonary Embolism: What Are …

Mount Sinai Endovascular Fellows Course

J. Giri

Update on HI-PEITHO - A Landmark Clinical Trial in PE

PERT Consortium 2022

K. Rosenfield

Pulmonary Embolism: Where Are We in 2024?

UPMC

B. Rivera-Lebron

Management of Acute Pulmonary Embolism: How Long Do You Treat?

NYU Langone

N. Amoroso

Thrombus Extending into the IVC

Venous Symposium

P. Muck

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for …

Keck School of Medicine of USC

L. Clavijo

Catheter-Directed Thrombolysis Is the Preferred Approach for the Tre…

PERT Consortium 2022

P. Monteleone

Catheter Wars: The Thrombus Strikes Back

AVA 2022 Annual Scientific Meeting

A. Bulmer, P. Carr

Regulatory Pathways for Devices for Management of Pulmonary Embolism…

PERT Consortium 2021

S. Lossef